Pristimerin exhibits in vitro and in vivo anticancer activities through inhibition of nuclear factor-кB signaling pathway in colorectal cancer cells
Keywords: Pristimerin; Colorectal cancer; NF-кB; HCT-116 cells; Akt; protein kinas B; CRC; colorectal cancer; IκBα; inhibitor of NF-κB; Ikk; IκBα kinase; LPS; lipopolysaccharide; MAPK; mitogen-activated protein kinase; NF-κB; nuclear factor-κB; MTT; 3-(4,5-